Secondary analysis of a phase II olaparib vs placebo maintenance trial in advanced endometrial carcinoma (130 evaluable): baseline ctDNA (19%) was independently associated with worse median PFS (1.81 vs 7.39 months; adjusted HR 5.33) and OS (adjusted HR 3.98).
Secondary analysisn = 130
Beinse et al. ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial